BioMarin (BMRN) Valuation Update After Six Straight Earnings Beats and Post-Restructuring Growth Momentum

BioMarin Pharmaceutical (BMRN) just posted its sixth straight quarter of beating Wall Street expectations, with Q2 earnings up roughly 124% year over year after its 2024 restructuring started lifting margins.

See our latest analysis for BioMarin Pharmaceutical.

Yet despite that earnings momentum, BioMarin’s 2025 year to date share price return is about minus 19 percent and its 1 year total shareholder return is similarly weak. This suggests sentiment has lagged improving fundamentals and upgraded guidance.

If BioMarin’s mix of pipeline news and restructuring progress has caught your attention, it might be worth comparing it with other specialist names across healthcare stocks for fresh ideas.

With earnings inflecting, margins expanding and the stock trading at a steep discount to analyst targets, investors now face a key question: is BioMarin a mispriced growth story, or is the market already discounting its next leg of expansion?

Most Popular Narrative: 39.8% Undervalued

Compared with the last close of $53.82, the most widely followed narrative implies a materially higher fair value, framing BioMarin as mispriced against its cash generation potential.

The analysts have a consensus price target of $96.593 for BioMarin Pharmaceutical based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $122.0, and the most bearish reporting a price target of just $60.0.

Read the complete narrative.

Want to see why this narrative leans into faster earnings growth than revenue, richer margins, and a punchy future earnings multiple that outpaces sector norms? Dive in to uncover the exact assumptions driving that gap between today’s share price and the projected fair value.

Result: Fair Value of $89.36 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upside case could be derailed by intensifying competition around Voxzogo and BMN 333, or by regulatory setbacks that push key launches further out.

Find out about the key risks to this BioMarin Pharmaceutical narrative.

Build Your Own BioMarin Pharmaceutical Narrative

If you want to stress test these assumptions yourself, or come to a different conclusion, you can build a bespoke view in just minutes: Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding BioMarin Pharmaceutical.

Ready for more investment ideas?

Strengthen your watchlist by looking beyond BioMarin, where carefully filtered opportunities based on fundamentals, growth and quality could sharpen your edge before the crowd even notices.

• Capture early momentum in niche innovators by scanning through these 3571 penny stocks with strong financials that already show balance sheet strength and disciplined execution.
• Position ahead of the next productivity wave by reviewing these 26 AI penny stocks that apply intelligent automation and data insights across real world industries.
• Explore potential value gaps by targeting these 908 undervalued stocks based on cash flows where current prices differ from long term cash flow potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com